INZY - Inozyme Pharma, Inc. Revenue Dynamics YoY (Last Twelve Months)

Narrow niche risks and trial complexities create volatility, as demonstrated by the 12-month revenue trajectory where the latest mark stands at 0.00. Meanwhile, management is effectively engaging with regulators to advance the therapy. Strong confidence from the medical community and the biotech's ethical image confirm the significant potential of Inozyme Pharma, Inc. (INZY) in treating rare genetic pathologies.
Inozyme Pharma Inc. (INZY) - metric breakdowns and financial figures

This indicator measures revenue dynamics over the last 12 months relative to the same period last year, allowing investors to track the pace of the business's operational recovery. By analyzing the annual change in revenue using the TTM method, one can assess how the stable interaction of Inozyme Pharma, Inc. (INZY) with contract manufacturers of enzyme drugs for the treatment of orphan diseases converts into real financial growth for the company.